FDA Posts Final Guidances on Adjuvant Therapies for Renal Cell and Bladder Cancer

The FDA outlined its latest thinking for sponsors of adjuvant therapies for renal cell and bladder cancer in two guidances released yesterday.
Source: Drug Industry Daily